Study to Evaluate New Drug AGN-151586 for the Treatment of Glabellar Lines

Recruiting
18 years - 99 years
All
Phase 3
20 participants needed
1 Location

Brief description of study

The purpose of this study is to test a new drug called AGN-151586 as a treatments for patients with moderate to severe frown lines between the eyebrows (glabellar) over a period of 18 weeks. Procedures include Vital signs, Physical Exam, Medical History, Blood and Urine tests, ECG, Neurological exam and questionnaires.

Detailed description of study

The purpose of this study is to test a new drug called AGN-151586 as a treatments for patients with moderate to severe frown lines between the eyebrows (glabellar) over a period of 18 weeks. Procedures include Vital signs, Physical Exam, Medical History, Blood and Urine tests, ECG, Neurological exam and questionnaires.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Glabellar Lines
  • Age: 18 years - 99 years
  • Gender: All

Adult male or female Age 18+ Moderate to severe frown (glabellar) lines between the eyebrows

Updated on 04 Aug 2024. Study ID: 851018

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center